contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


micropos-medical-velindre-cancer-center-enters-agreement-for-the-implementation-of-the-raypilot-system

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Micropos Medical operates in medical technology. The company's products are used in radiotherapy. The vision is to develop a technology that will pinpoint diseases during said treatment, where product development is based on an electromagnetic positioning system. The product creates real-time information and is used primarily for the treatment of prostate cancer, but also for other tumor treatments. The company was established in 2003 and has its headquarters in Gothenburg.

Micropos Medical

Micropos Medical has entered into an agreement with Velindre Cancer Center to implement the Raypilot System, enabling high-precision radiation therapy for prostate cancer.As part of the collaboration...

<div class="abstract">Micropos Medical has entered into an agreement with Velindre Cancer Center to implement the Raypilot System, enabling high-precision radiation therapy for prostate cancer.</div>As part of the collaboration, Dr. Nachi Palaniappan and his team will implement ASBRT, with the aim of establishing the workflow and ultimately integrating the method as part of the clinic's standardized care for prostate cancer."Within prostate cancer care, the focus is increasingly shifting toward quality of life after treatment. ASBRT demonstrates excellent clinical outcomes with fewer side effects, while enabling treatment in as little as three to five days," says Richard Forsberg, CEO of Micropos Medical.Installation of the system and treatment of the first patient are planned for the first quarter of 2026.Dr. Nachi Palaniappan, Lead Radiation Oncologist at Velindre Cancer Center, comments: "We have previous experience with SBRT, and this collaboration allows us to take the next step toward even greater precision and enhanced patient quality of life. The Raypilot System enables real-time tracking of prostate motion, reduces radiation exposure to healthy tissue, and allows for increased tumor dosage. This results in improved treatment outcomes and fewer side effects. Additionally, the system eliminates the need for surgically implanted gold markers."Advancing the Role of Modern Radiation TherapyMicropos Medical continues to strengthen awareness of modern radiation therapy as an effective and patient-friendly treatment option for prostate cancer among both patients and healthcare providers."There is strong and growing evidence that modern radiation therapy delivers excellent clinical results with clear benefits for patients. Our collaboration with Velindre Cancer Center marks an important step, and we look forward to enabling broader patient access to ASBRT as a standard treatment," concludes Richard Forsberg.<div></div>

Micropos Medical: Velindre Cancer Center Enters Agreement for the Implementation of the Raypilot System